Marrone Bio Innovations Joins United Nations Global Compact & Launches Environmental, Social & Governance Initiative Biological Crop Protection Company Leads the Industry with Independent Climate Impact Assessment of Products
March 29, 2021 08:31 ET | Source: Marrone Bio Innovations Marrone Bio Innovations Davis, California, UNITED STATES
DAVIS, Calif., March 29, 2021 (GLOBE NEWSWIRE) Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, announced today it has joined the United Nations (UN) Global Compact, the world’s largest corporate sustainability initiative committed to aligning business strategy and operations with universal principles on human rights, labor, environment and anti-corruption.
“Sustainability has been one of the cornerstones of Marrone Bio Innovations since our beginning in 2006,” states Kevin Helash, Chief
Marrone Bio Innovations leading the charge toward more environmentally-conscious effective pest management for farmers
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Marrone Bio Innovations leading the charge toward more environmentally-conscious effective pest management for farmers
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Marrone Bio gets boosted $3.50 price target and repeat Buy rating from Canaccord Genuity
Analyst Bobby Burleson noted that the Marrone management team is speeding up the commercialization process and tightening its focus Marrone Bio holds more than 400 issued and pending patents and has brought six US EPA-registered biological product lines and one biostimulant to market
Marrone Bio Innovations Inc (NASDAQ:MBII) (FRA:0MB) shares climbed Friday after an analyst at Canaccord Genuity upped the price target for the company to $3.50 from $2 and reiterated a Buy rating.
The company introduced a 2022 revenue projection of $7.7 million based on “a continuing shift to seed and soil treatments and plant health solutions,” with an EBITDA of $1.2 million.